Skip to Content

AbCellera Biologics Inc Ordinary Shares ABCL

Morningstar Rating
$2.90 −0.04 (1.36%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ABCL is trading at a 187% premium.
Price
$2.91
Fair Value
$9.85
Uncertainty
Extreme
1-Star Price
$366.68
5-Star Price
$7.99
Economic Moat
Hsrz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABCL is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.94
Day Range
$2.892.97
52-Week Range
$2.868.05
Bid/Ask
$2.92 / $3.00
Market Cap
$852.76 Mil
Volume/Avg
2.5 Mil / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
23.53
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
586

Comparables

Valuation

Metric
ABCL
NYKD
BAI
Price/Earnings (Normalized)
Price/Book Value
0.752.76
Price/Sales
23.5339.817.31
Price/Cash Flow
Price/Earnings
ABCL
NYKD
BAI

Financial Strength

Metric
ABCL
NYKD
BAI
Quick Ratio
7.318.432.08
Current Ratio
7.768.433.65
Interest Coverage
−233.69
Quick Ratio
ABCL
NYKD
BAI

Profitability

Metric
ABCL
NYKD
BAI
Return on Assets (Normalized)
−5.95%−18.26%−38.46%
Return on Equity (Normalized)
−7.61%−23.64%
Return on Invested Capital (Normalized)
−10.11%−26.98%−47.53%
Return on Assets
ABCL
NYKD
BAI
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
LlzgbzbjfCqx$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
FsrzfdlrfKlmzrm$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
ZncnykfnXqrydcs$116.0 Bil
Moderna Inc
MRNA
HbbcnbmDtzh$51.1 Bil
argenx SE ADR
ARGX
CtddnjbRddbl$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
TcnscmyQrsxx$21.0 Bil
BioNTech SE ADR
BNTX
PmxvkzymPnrhx$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
TggwtntVwtvyf$15.9 Bil
United Therapeutics Corp
UTHR
HyhzqmtPvpt$14.0 Bil
Incyte Corp
INCY
JtbpfrhfZrrvjc$12.5 Bil

Sponsor Center